MannKind Corporation

MannKind Corporationverified

MNKD

Price:

$6.74

Market Cap:

$1.86B

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect ...[Read more]

Industry

Biotechnology

IPO Date

2004-07-28

Stock Exchange

NASDAQ

Ticker

MNKD

The Current Ratio as of December 2024 (TTM) for MannKind Corporation (MNKD) is 4.54

According to MannKind Corporation’s latest financial reports and current stock price. The company's current Current Ratio is 4.54. This represents a change of 13.34% compared to the average of 4.01 of the last 4 quarters.

MannKind Corporation (MNKD) Historical Current Ratio (quarterly & annually)

How has MNKD Current Ratio performed in the past?

The mean historical Current Ratio of MannKind Corporation over the last ten years is 1.70. The current 4.54 Current Ratio has changed 26.64% with respect to the historical average. Over the past ten years (40 quarters), MNKD's Current Ratio was at its highest in in the December 2021 quarter at 4.54. The Current Ratio was at its lowest in in the March 2016 quarter at 0.18.

Quarterly (TTM)
Annual

Average

1.70

Median

1.00

Minimum

0.29

Maximum

4.54

MannKind Corporation (MNKD) Current Ratio by Quarter and Year

Discovering the peaks and valleys of MannKind Corporation Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 321.49%

Maximum Annual Current Ratio = 4.54

Minimum Annual Increase = -42.72%

Minimum Annual Current Ratio = 0.29

Quarterly (TTM)
Annual
YearCurrent RatioChange
20233.592.74%
20223.49-23.20%
20214.54321.49%
20201.0816.46%
20190.93-14.89%
20181.0966.55%
20170.65-22.41%
20160.84194.67%
20150.29-42.72%
20140.50-16.45%

MannKind Corporation (MNKD) Average Current Ratio

How has MNKD Current Ratio performed in the past?

The current Current Ratio of MannKind Corporation (MNKD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

3.87

5-year avg

2.73

10-year avg

1.70

MannKind Corporation (MNKD) Current Ratio vs. Peers

How is MNKD’s Current Ratio compared to its peers?

MannKind Corporation’s Current Ratio is greater than BioMarin Pharmaceutical Inc. (4.27), less than Vaxcyte, Inc. (17.88), less than Liquidia Corporation (6.33), less than Legend Biotech Corporation (4.98), less than Bio-Techne Corporation (4.56), less than United Therapeutics Corporation (4.58), less than Larimar Therapeutics, Inc. (13.10), less than Day One Biopharmaceuticals, Inc. (14.62), greater than Kiniksa Pharmaceuticals, Ltd. (3.24), greater than Verastem, Inc. (3.23), less than ImmunoGen, Inc. (5.47), less than Immutep Limited (13.81), greater than Intercept Pharmaceuticals, Inc. (4.22), less than Elevation Oncology, Inc. (17.77), less than Acer Therapeutics Inc. (0), greater than NRx Pharmaceuticals, Inc. (0.10), greater than Pasithea Therapeutics Corp. (0.20), less than SAB Biotherapeutics, Inc. (14.81), greater than MiNK Therapeutics, Inc. (3.69), greater than Affimed N.V. (0.89), greater than Adaptimmune Therapeutics plc (1.93), greater than Sangamo Therapeutics, Inc. (3.85), greater than null (1.35),

Build a custom stock screener for MannKind Corporation (MNKD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MannKind Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

MannKind Corporation (MNKD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like MannKind Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Current Ratio?

How can you use the Current Ratio?

What is MannKind Corporation's Current Ratio?

How is the Current Ratio calculated for MannKind Corporation (MNKD)?

What is the highest Current Ratio for MannKind Corporation (MNKD)?

What is the 3-year average Current Ratio for MannKind Corporation (MNKD)?

What is the 5-year average Current Ratio for MannKind Corporation (MNKD)?

How does the current Current Ratio for MannKind Corporation (MNKD) compare to its historical average?